liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
Åvall-Lundqvist, Elisabeth, Professor
Alternative names
Publications (10 of 83) Show all publications
Olsson, C., Wilde Larsson, B., Larsson, M., Holmberg, E., Marcickiewicz, J., Tholander, B., . . . Borgfeldt, C. (2022). Adaption of the Quality From the Patient’s Perspective Instrument for Use in Assessing Gynecological Cancer Care and Patients’ Perceptions of Quality Care Received. Cancer Care Research Online, 2(1), e019-e019
Open this publication in new window or tab >>Adaption of the Quality From the Patient’s Perspective Instrument for Use in Assessing Gynecological Cancer Care and Patients’ Perceptions of Quality Care Received
Show others...
2022 (English)In: Cancer Care Research Online, E-ISSN 2691-3623, Vol. 2, no 1, p. e019-e019Article in journal (Refereed) Published
Abstract [en]

Background: Research focusing on patients’ perceptions of the quality of gynecological cancer care is needed.

Objective: To adapt the Quality from the Patient’s Perspective instrument for use in gynecological cancer care (QPP-GynCa) and describe patients’ perceptions of their quality of care in terms of the care received and the subjective importance of the aspects of care.

Methods: A cross-sectional study 6–8 months after diagnosis was conducted, involving 1511 patients (response rate of 50.4%) included in the Swedish quality registry for gynecologic cancer.

Results: The exploratory factor analysis (n = 1431) resulted in the QPP-GynCa with a 5-factor structure and an eigenvalue of ≥1, explaining 73.1% of the total scale variance. The final 27-item version of the QPP-GynCa consisted of 18 items with 8 additional single items and 1 global single item. The Cronbach’s alpha was acceptable for most factors (>.80). Subjective importance scores were higher than corresponding quality of care scores for care received (P ≤ .01)in all dimensions, factors, and items.

Conclusions: The QPP-GynCa instrument reflects all 4 dimensions of the theoretical model of quality of care and achieved good validity as a reliable instrument in assessing the quality of gynecological cancer care.

Implication for Practice: Information related to self-care, aspects of sexuality, and reducing patient waiting times need improvement.

What Is Foundational: This study contributes to a better understanding of quality of gynecological cancer treatment and care. The validated QPP-GynCa instrument will be a platform for more research on how this group of patients experience their received care, as well as importance of each aspect of care.

Place, publisher, year, edition, pages
Wolters Kluwer, 2022
Keywords
factor analysis; gynecological cancer care; instrument development; patient perspectives; quality of health care
National Category
Nursing Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-192131 (URN)10.1097/cr9.0000000000000019 (DOI)
Available from: 2023-03-03 Created: 2023-03-03 Last updated: 2023-03-23
Engvall, K., Gréen, H., Fredrikson, M., Lagerlund, M., Lewin, F. & Åvall-Lundqvist, E. (2022). Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study. Breast Cancer Research and Treatment, 195, 379-391
Open this publication in new window or tab >>Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study
Show others...
2022 (English)In: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 195, p. 379-391Article in journal (Refereed) Published
Abstract [en]

Background We explored the impact of persistent sensory and motor taxane-induced peripheral neuropathy (TIPN) symptoms on health-related quality of life (HRQL) among early-stage breast cancer survivors (ESBCS). Methods A population-based cohort of 884 residual-free ESBCS received a postal questionnaire, including the EORTC chemotherapy-induced PN (CIPN20) and the EORTC QLQ-C30 instruments. Mean scores of QLQ-C30 scales among ESBCS with and without TIPN were calculated and adjusted for confounding factors (age, lifestyle factors, co-morbidities; linear regression analyses). Interpretation of QLQ-C30 results were based on guidelines. Results Response rate was 79%, and 646 survivors were included in the analysis. In median, 3.6 (1.5-7.3) years had elapsed post-taxane treatment. All TIPN symptoms had a significant impact on global QoL, which worsened with increased severity of TIPN. Between 29.5% and 93.3% of ESBCS with moderate-severe TIPN reported a clinical important impairment of functioning and personal finances, 64.3-85.7% reporting "difficulty walking because of foot drop," and 53.1-81.3% reporting "problems standing/walking because of difficulty feeling ground under feet" had impaired functioning/finances. The difference in mean scores between affected and non-affected survivors was highest for "numbness in toes/feet" and "difficulty walking because of foot drop." Moderate-severe "difficulty climbing stairs or getting out of chair because of weakness of legs" and "problems standing/walking because of difficulty feeling ground under feet" were associated with the largest clinically important differences on all scales. Conclusion Persistent sensory and motor TIPN is associated with clinically relevant impairment of global QoL, functioning, and personal finances among ESBCS, which increased with level of TIPN severity.

Place, publisher, year, edition, pages
Springer, 2022
Keywords
Adjuvant therapy; Chemotherapy; Taxane; Chemotherapy-Induced Peripheral Neuropathy CIPN; Taxane-induced peripheral neuropathy; Survivorship; Breast cancer survivorship; QLQ-C30; CIPN20; Quality of life; Health-related quality of life; Functional health; Financial toxicity
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
urn:nbn:se:liu:diva-187717 (URN)10.1007/s10549-022-06670-9 (DOI)000837571200001 ()35941422 (PubMedID)
Note

Funding Agencies|Linkoping University; Swedish Cancer Society [190224]; Medical Research Council of Southeast Sweden [FORSS-932359]; FuturumThe Academy for Health and Care, Jonkoping County Council [575361]; Forsknings-ALF [LIO-901261]

Available from: 2022-08-29 Created: 2022-08-29 Last updated: 2023-05-04Bibliographically approved
Radestad, A. F., Dahm-Kahler, P., Holmberg, E., Bjurberg, M., Hellman, K., Högberg, T., . . . Borgfeldt, C. (2022). Long-term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) study. Acta Obstetricia et Gynecologica Scandinavica, 101(8), 923-930
Open this publication in new window or tab >>Long-term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) study
Show others...
2022 (English)In: Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, E-ISSN 1600-0412, Vol. 101, no 8, p. 923-930Article in journal (Refereed) Published
Abstract [en]

Introduction Minimally invasive methods to reduce menorrhagia were introduced in the 1980s and 1990s. Transcervical endometrial resection (TCRE) and endometrial ablation (EA) are two of the most frequently used methods. As none of them can guarantee a complete removal of the endometrium, there are concerns that the remaining endometrium may develop to endometrial cancer (EC) later in life. The primary aim was to analyze the long-term incidence of EC after TCRE and EA in a nationwide population. The secondary aim was to assess the two treatment modalities separately. Material and Methods The Swedish National Patient Registry and National Quality Registry for Gynecological Surgery were used for identification of women who had TCRE or EA performed between 1997-2017. The cohort was followed from the first TCRE or EA until hysterectomy, diagnosis of EC, or death. Follow-up data were retrieved from the National Cancer Registry and the National Death Registry. Expected incidence for EC in Swedish women was calculated using Swedish data retrieved from the NORDCAN project after having taken into account differences of age and follow-up time. Cumulative incidence of EC after TCRE and EA, was calculated. A standardized incidence ratio was calculated based on the expected and observed incidence, stratified by age and year of diagnosis. Results In total, 17 296 women (mean age 45.1 years) underwent TCRE (n = 8626) or EA (n = 8670). Excluded were 3121 who had a hysterectomy for benign causes during follow up. During a median follow-up time of 7.1 years (interquartile range 3.1-13.3 years) the numbers of EC were 25 (0.3%) after TCRE and 2 (0.02%) after EA, respectively. The observed incidence was significantly lower than expected (population-based estimate) after EA but not after TCRE, giving a standardized incidence ratio of 0.13 (95% confidence interval [CI] 0.03-0.53) after EA and 1.27 (95% CI 0.86-1.88) after TCRE. Median times to EC were 3.0 and 8.3 years after TCRE and EA, respectively. Conclusions There was a significant reduction of EC after EA, suggesting a protective effect, whereas endometrial resection showed an incidence within the expected rate.

Place, publisher, year, edition, pages
WILEY, 2022
Keywords
endometrial ablation; endometrial cancer incidence; endometrial cancer risk; menorrhagia; transcervical endometrial resection
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-185831 (URN)10.1111/aogs.14385 (DOI)000805401100001 ()35624547 (PubMedID)
Note

Funding Agencies|Swedish Cancer Society

Available from: 2022-06-15 Created: 2022-06-15 Last updated: 2023-02-09Bibliographically approved
Lee, Y. C., King, M. T., OConnell, R. L., Lanceley, A., Joly, F., Hilpert, F., . . . Friedlander, M. L. (2022). Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. International Journal of Gynecological Cancer, 32(6), 761-768
Open this publication in new window or tab >>Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Show others...
2022 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 32, no 6, p. 761-768Article in journal (Refereed) Published
Abstract [en]

Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially platinum sensitive with >= 3 lines of chemotherapy (PPS-ROC >= 3). Methods Participants completed the Measure of Ovarian Cancer Symptoms and Treatment (MOST) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 questionnaires at baseline and every 3-4 weeks until progression. Participants were classified symptomatic if they rated >= 4 of 10 in at least one-third of symptoms in the MOST index. Improvement in MOST was defined as two consecutive scores of <= 3 in at least half of the symptomatic items at baseline. Improvement in HRQL was defined as two consecutive scores >= 10 points above baseline in the QLQ-C30 summary score scale (range 0-100). Results Of 948 participants enrolled, 910 (96%) completed baseline questionnaires: 546 with PRR-ROC and 364 with PPS-ROC >= 3. The proportions of participants symptomatic at baseline as per MOST indexes were: abdominal 54%, psychological 53%, and disease- or treatment-related 35%. Improvement was reported in MOST indexes: abdominal 40%, psychological 35%, and disease- or treatment-related 38%. Median time to improvement in abdominal symptoms occurred earlier for PRR-ROC than for PPS-ROC >= 3 (4 vs 6 weeks, p=0.044); median duration of improvement was also similar (9.0 vs 11.7 weeks, p=0.65). Progression-free survival was longer among those with improvement in abdominal symptoms than in those without (median 7.2 vs 2.5 months, p<0.0001). Improvements in HRQL were reported by 77/448 (17%) with PRR-ROC and 61/301 (20%) with PPS-ROC >= 3 (p=0.29), and 102/481 (21%) of those with abdominal symptoms at baseline. Conclusion Over 50% of participants reported abdominal and psychological symptoms at baseline. Of those, 40% reported an improvement within 2 months of starting chemotherapy. Approximately one in six participants reported an improvement in HRQL. Symptom monitoring and supportive care is important as chemotherapy palliated less than half of symptomatic participants.

Place, publisher, year, edition, pages
BMJ Publishing Group, 2022
Keywords
ovarian cancer; quality of life (PRO); palliative care; medical oncology
National Category
Obstetrics, Gynecology and Reproductive Medicine
Identifiers
urn:nbn:se:liu:diva-182926 (URN)10.1136/ijgc-2021-003142 (DOI)000748913800001 ()35086926 (PubMedID)2-s2.0-85131701918 (Scopus ID)
Note

Funding Agencies|NHMRCNational Health and Medical Research Council of Australia [1063012, 570893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UKCancer Research UK; UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer AustraliaAustralian Government; NHMRC Program grantNational Health and Medical Research Council of Australia; Department of HealthEuropean Commission

Available from: 2022-02-17 Created: 2022-02-17 Last updated: 2023-03-30Bibliographically approved
Åvall-Lundqvist, E. (2020). Classification of Endometrial Cancer. In: Mansoor R. Mirza (Ed.), Management of Endometrial Cancer: (pp. 3-6). Cham: Springer
Open this publication in new window or tab >>Classification of Endometrial Cancer
2020 (English)In: Management of Endometrial Cancer / [ed] Mansoor R. Mirza, Cham: Springer, 2020, p. 3-6Chapter in book (Refereed)
Abstract [en]

Endometrial cancer is the most common malignancy of the female genital tract in the more developed regions of the world [1]. Stage of disease, i.e., the extent of tumor spread at the time of presentation, is the most significant prognostic parameter.

Place, publisher, year, edition, pages
Cham: Springer, 2020
Keywords
Endometrial Cancer, Hormonal Interactions, Hereditary Cancers, Genetic Classification, Guidelines, Surgical Principles, Radiation Therapy
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-163830 (URN)10.1007/978-3-319-64513-1 (DOI)9783319645124 (ISBN)9783319645131 (ISBN)
Available from: 2020-02-21 Created: 2020-02-21 Last updated: 2020-02-21Bibliographically approved
Heitz, F., Harter, P., Åvall-Lundqvist, E., Reuss, A., Pautier, P., Cormio, G., . . . du Bois, A. (2019). Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecologic Oncology, 152(2), 235-242
Open this publication in new window or tab >>Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
Show others...
2019 (English)In: Gynecologic Oncology, ISSN 0090-8258, E-ISSN 1095-6859, Vol. 152, no 2, p. 235-242Article in journal (Refereed) Published
Abstract [en]

Objective. Surgical assessment of residual tumor provides the strongest prognostic information in advanced ovarian cancer (AOC), with the best outcome observed after complete resection. Postoperative radiological assessment before initiation of chemotherapy can supplement the information obtained by surgical assessment; however, it may also reveal conflicting findings. Methods. Patients with AOC enrolled in the AGO-OVAR 12 trial underwent baseline imaging before the first chemotherapy cycle. The findings from surgical and radiologic assessment for disease extend were compared. Additionally, an integrated approach was assessed. Results. Complete data from all 3 assessment methods were available for 1345 patients. Of 689 patients with complete resection, tumor was observed in 28% and 22% of patients undergoing radiologic and integrated assessment, respectively. Patients with surgical- radiological and surgical-integrated concordant findings showed a 5-year overall survival (5Y-OS) of 72% and 71%, whereas patients with surgical-radiological and surgical-integrated discordant results showed inferior 5Y-OS of 47% and 49%, respectively. Patients with surgically assessed residual disease had a 5-YOS of 37%. The interval between surgery and baseline assessment was independently associated with discordance between assessment methods, which might reflect early tumor regrowth. Conclusions. Baseline tumor assessment before chemotherapy provides information that stratifies patients with complete resection into different prognostic groups. Integrating the data from different assessment methods might lead to improved definitions of prognostic groups. Further investigation to determine if earlier initiation of chemotherapy after debulking surgery could increase survival of patients with early tumor regrowth is warranted. (C) 2018 Published by Elsevier Inc.

Place, publisher, year, edition, pages
ACADEMIC PRESS INC ELSEVIER SCIENCE, 2019
Keywords
Advanced ovarian cancer; Debulking surgery; Pre-chemotherapy imaging; Prognosis
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-155010 (URN)10.1016/j.ygyno.2018.11.008 (DOI)000459089600004 ()30466805 (PubMedID)
Available from: 2019-03-20 Created: 2019-03-20 Last updated: 2020-04-27
Salehi, S., Åvall-Lundqvist, E., Brandberg, Y., Johansson, H., Suzuki, C. & Falconer, H. (2019). Lymphedema, serious adverse events, and imaging 1 year after comprehensive staging for endometrial cancer: results from the RASHEC trial. International Journal of Gynecological Cancer, 29(1), 86-93
Open this publication in new window or tab >>Lymphedema, serious adverse events, and imaging 1 year after comprehensive staging for endometrial cancer: results from the RASHEC trial
Show others...
2019 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 29, no 1, p. 86-93Article in journal (Refereed) Published
Abstract [en]

Background and Objectives In the Robot Assisted Surgery for High Risk Endometrial Cancer (RASHEC) trial, patients with high-risk endometrial cancer were randomly assigned to robot-assisted laparoscopic surgery (RALS) or laparotomy for pelvic and infrarenal para-aortic lymph node dissection. We here report on self-reported lower limb lymphedema (LLL), lymphocyst formation, ascites, and long-term serious adverse events 12 months after surgery. Patients and methods Patients were enrolled between 2013 and 2016, and 96 patients were included in the per protocol analysis, evenly distributed between RALS and laparotomy. Self-reported LLL was recorded using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for endometrial cancerEN24, assessed before and 12 months after surgery. Computed tomography was assessed at baseline, 3, and 12 months. Medical charts were reviewed for serious adverse events and hospital admissions 31 to 365 days after surgery. Results At 12 months after laparotomy and RALS, 61% and 50% patients, respectively, reported LLL (p = 0.31). In univariate analysis, the mean score of LLL at 12 months was significantly higher for laparotomy than for RALS (p amp;lt; 0.05) and for those without abdominal drainage (p = 0.02), but was not independently associated with LLL in the multivariate analysis. Imaging showed no significant difference in lymphocyst formation or ascites between surgical modalities. No difference was found in serious adverse events and admissions to hospital for any reason. There was no agreement between lymphocyst formation or ascites and self-reported LLL. Conclusion Follow-up 1 year after comprehensive surgical staging for high-risk endometrial cancer showed no differences in self-reported LLL, findings on imaging, or SAE between laparotomy and robot-assisted surgery.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS, 2019
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-155614 (URN)10.1136/ijgc-2018-000019 (DOI)000459687700012 ()30640688 (PubMedID)
Available from: 2019-03-21 Created: 2019-03-21 Last updated: 2020-04-27
Bagge, E., Beiron, U., Malander, S., Rosenberg, P. & Åvall-Lundqvist, E. (2019). Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study. Acta Oncologica, 58(3), 320-325
Open this publication in new window or tab >>Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study
Show others...
2019 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 58, no 3, p. 320-325Article in journal (Refereed) Published
Abstract [en]

Aim of the study: Endocrine treatment (ET) is an alternative as salvage therapy in epithelial ovarian cancer (EOC) but the usage in routine care is unknown. We evaluated the treatment patterns and outcome of patients receiving ET for EOC in the Southeast medical region in Sweden.Method: Patients were identified through the population-based Southeast Quality Registry for gynaecological cancer. Inclusion criteria were: age 18 years, histologically verified EOC diagnosed 2000-2013, ET for 4 weeks. Coverage compared with the Swedish National Cancer Registry was 100%. Data extracted from medical records was collected by means of a study-specific Case Report Form. Last date of follow-up was February 1st, 2018. All statistics were descriptive.Results: Altogether 248 (18%) of 1414 patients were treated with ET. Most (49%) had received only one, and 34% two previous lines of chemotherapy. Time from last chemotherapy to ET was 4 months, range 0-55months. The reason for initiating ET was tumor progression (66%), chemotherapy related toxicity (29%) and maintenance (4%). Tamoxifen was prescribed in 94% of cases. Best response was partial (amp;lt; 5%) and stable disease (50%). No patient had a complete response. 194 (78%) patients received subsequent chemotherapy, of these 27% had 3-7 lines of chemotherapy. Duration of ET was a median 4 months (range 1-80 months). Median time from ET to subsequent chemotherapy was 5 months (range 0-79). The median overall survival was 45 months (range 9-173).Conclusion: In the Southeast region of Sweden, endocrine treatment for EOC was prescribed inconsistently and in various settings, usually initiated by a rising CA-125 level. Poorer documentation and irregular tumor response assessment were observed for endocrine treatment compared to chemotherapy.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2019
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-156574 (URN)10.1080/0284186X.2018.1546061 (DOI)000462947900009 ()30632888 (PubMedID)
Note

Funding Agencies|Medical Research Council of Southeast Sweden; ALF Grants, Region Ostergotland

Available from: 2019-05-15 Created: 2019-05-15 Last updated: 2020-04-27
Fuglsang, K., Haldorsen, I. S., Åvall-Lundqvist, E., Lindahl, G., Roed, H., Woie, K., . . . Blaakaer, J. (2018). Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countriesSurvey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology. Acta Obstetricia et Gynecologica Scandinavica, 97(10), 1178-1184
Open this publication in new window or tab >>Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countriesSurvey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology
Show others...
2018 (English)In: Acta Obstetricia et Gynecologica Scandinavica, ISSN 0001-6349, E-ISSN 1600-0412, Vol. 97, no 10, p. 1178-1184Article in journal (Refereed) Published
Abstract [en]

IntroductionWomen with cervical cancer in the Nordic countries are increasingly undergoing pretreatment imaging by ultrasound, magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT) or computed tomography, or sentinel lymph node procedure. The present survey reports the influence of pretreatment imaging findings on the recorded clinical International Federation of Gynecology and Obstetrics (FIGO) stage in Nordic countries and its impact on treatment planning and preferred surgical approach in cervical cancer. Material and methodsThe Nordic Society of Gynecological Oncology Surgical Subcommittee developed a questionnaire-based survey that was conducted from 1 January to 31 March 2017. All the 22 Nordic Gynecological Oncology Centers (Denmark 5, Finland 5, Iceland 1, Norway 4, and Sweden 7) were invited to participate. ResultsThe questionnaires were returned by 19 of 22 (86.3%) centers. The median number (range) of women with cervical cancer treated at each center annually was 32 (15-120). In 58% (11/19) of the centers, imaging findings were reported to influence the clinical staging. MRI in combination with PET-CT was the preferred imaging method and the results influenced treatment planning. Robotic-assisted radical hysterectomy was the preferred surgical method in 72% (13/18) of the centers. Sentinel lymph node procedure was not routinely implemented in the majority of the Nordic centers. ConclusionMore than half of the Nordic Gynecological Oncology Centers already report a clinical FIGO stage influenced by pretreatment imaging findings. The trend in preferred treatment is robotic-assisted radical hysterectomy and the sentinel lymph node procedure is gradually being introduced.

Place, publisher, year, edition, pages
WILEY, 2018
Keywords
diagnostic imaging; gynecological surgical procedure; International Federation of Gynecology and Obstetrics; neoplasm staging; Nordic Society of Gynecological Oncology; pretreatment elaboration; sentinel lymph node; uterine cervical neoplasm
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:liu:diva-151632 (URN)10.1111/aogs.13388 (DOI)000444070900005 ()29799176 (PubMedID)
Available from: 2018-09-27 Created: 2018-09-27 Last updated: 2019-05-01
Cibula, D., Poetter, R., Planchamp, F., Åvall-Lundqvist, E., Fischerova, D., Haie-Meder, C., . . . Raspollini, M. R. (2018). Correction: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 472, pg 919, 2018). Virchows Archiv, 472(6), 937-938
Open this publication in new window or tab >>Correction: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer (vol 472, pg 919, 2018)
Show others...
2018 (English)In: Virchows Archiv, ISSN 0945-6317, E-ISSN 1432-2307, Vol. 472, no 6, p. 937-938Article in journal (Other academic) Published
Abstract [en]

n/a

Place, publisher, year, edition, pages
Springer, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-149728 (URN)10.1007/s00428-018-2380-7 (DOI)000435410300006 ()29789924 (PubMedID)2-s2.0-85048484962 (Scopus ID)
Note

Correction to: Virchows Arch (2018)

 https://doi.org/10.1007/s00428-018-2362-9

Two corrections were made to the above publication following its original online publication on 4th May 2018.

Available from: 2018-07-24 Created: 2018-07-24 Last updated: 2019-04-17Bibliographically approved
Organisations

Search in DiVA

Show all publications